# The ADAPT Platform fast-tracks development of tomorrow’s mental health research and clinical tools

The ADAPT Platform™ curates information on biologically-relevant gene network pathways indicated in neuropsychiatric conditions — including anxiety, depression, alcohol/substance use disorder, ADHD, PTSD, and TBI (ADAPT) — for researchers pushing the boundaries of what is possible in mental and brain health R&D.

[ADAPT One-Sheet](https://drive.google.com/file/d/1QWajb3w68UipnWGeV9q0wdbmeYK7iMWR/view?usp=sharing)

[Contact Us for Technical One-Sheet](mailto:amadeus@polarisgenomics.com?subject=Urgent%20-%20Website%20Inquiry%20Re:%20ADAPT%20Panel)

## About the ADAPT Platform™

ADAPT is advancing liquid biopsy for CNS conditions by identifying targets for drug and clinical tool development.

ADAPT analyzes genetic association, transcriptomic, and clinical phenotypic data, defining RNA expression profiles correlated with neuropsychiatric conditions and treatment response. These profiles, tied to 1000+ specific genomic biomarker targets for mental and brain health, are accessible to our research partners.

## Add ADAPT to your workflow

Is your lab interrogating a neuropsychiatric condition or related trait? With just 3ml blood samples, using the ADAPT Platform™ is simple.

ADAPT is continuously updated with new data, providing academic, pharma, and biotech labs with the most up-to-date, accurate, and objective resource for developing biology-based diagnostics and therapeutics.

## Together, let's blaze the way

Transforming the mental health landscape takes a village. At Polaris, we actively welcome collaborations with researchers and leadership across pharma, academic, clinical, CRO, government, and other neuropsychiatric partners.